← All trials
NCT03379493
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 4, 2018
- Primary completion
- Dec 10, 2024
- Completion date
- Dec 10, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 54
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Aeon Therapeutics (Shanghai) Co., Ltd.Lead sponsor
- Duke UniversityCollaborator
- Duke UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.